GSA Capital Partners LLP Buys 88,892 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Key Points

• GSA Capital Partners LLP increased its holdings in Xeris Biopharma by 178.3% during the first quarter, acquiring an additional 88,892 shares.
• Xeris Biopharma's stock rose 5.7%, currently trading at $5.38, with a market cap of $841.32 million.
• Analysts have provided mixed ratings on Xeris, with Oppenheimer raising the price target to $7.00 while Wall Street Zen downgraded the stock to a "hold" rating.

GSA Capital Partners LLP lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 178.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,735 shares of the company's stock after purchasing an additional 88,892 shares during the period. GSA Capital Partners LLP owned 0.09% of Xeris Biopharma worth $762,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after buying an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after buying an additional 3,847 shares during the period. Apollon Wealth Management LLC raised its stake in Xeris Biopharma by 19.8% during the 1st quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock worth $133,000 after buying an additional 4,000 shares during the period. Prudential Financial Inc. raised its stake in Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock worth $125,000 after buying an additional 7,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Xeris Biopharma by 5.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock worth $578,000 after buying an additional 9,506 shares during the period. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Up 5.7%

Shares of Xeris Biopharma stock opened at $5.38 on Friday. The company has a market cap of $841.32 million, a PE ratio of -17.93 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.10 and a 52 week high of $6.07. The business has a 50 day moving average price of $4.84 and a 200-day moving average price of $4.48.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analysts' expectations of $57.61 million. As a group, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on XERS. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Wall Street Zen downgraded Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch purchased 25,000 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The stock was bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. The trade was a 1.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.47% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.